Vertex's Kalydeco combo falls short in trial; NICE nixes Celgene's Imnovid; J&J marketing new Velcade use in U.K.;

> Vertex Pharmaceuticals ($VRTX) disappointed investors with data from a cystic fibrosis combo trial in which its experimental drug VX-661 plus Kalydeco didn't improve pulmonary function as much as expected. Report

> The National Institute for Health and Care Excellence stiff-armed Celgene's ($CELG) multiple myeloma treatment Imnovid (pomalidomide), saying the third-line treatment was too costly for routine use. Report

> Johnson & Johnson ($JNJ) is rolling out a marketing campaign for Velcade in the U.K., where the drug recently won approval for a new indication in mantle cell lymphoma. Report

> Everyday Health bought the rare-disease advertising agency Cambridge BioMarketing in a deal worth about $38 million, aiming to capitalize on marketing opportunities in diseases with small patient populations. Report

> England's National Health Service is launching a directory of mental health apps it endorses for patients. Report

And Finally... An upscale lifestyle magazine just for doctors? Yep. Report

Suggested Articles

GSK's consumer health chief digital officer Marc Speichert was not on the stage this year at Lions Health, but meeting with potential partners.

If marketing is a persuasion business, why can’t a room full of marketing experts figure out how to change skeptics’ minds about vaccines?

China is already floating in an ocean of data, and the sea level rises every day. But these are uncharted waters—and that’s an opportunity for pharma.